The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Abstract
Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (P less than 0.001) and 28 percent in those treated with 1 million units (P less than 0.02), but only 8 percent in untreated patients. The serum alanine aminotransferase level became completely normal in 22 of the 26 patients (85 percent) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56 percent) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histologic improvement because of the regression of lobular and periportal inflammation. Relapse within six months after the completion of treatment occurred in 51 percent of the patients treated with 3 million units of interferon and 44 percent of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis
Kuo, G., Choo, Q.-L., Alter, H. J., Gitnick, G. L., Redeker, A. G., Purcell, R. H., Miyamura, T., Dienstag, J. L., Alter, M. J., Stevens, C. E., et al. (1989) · Science · doi:10.1126/science.2496467 · Cited by 3,346
Self-citationTreatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon
Hoofnagle, J. H., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J. G., Park, Y., & Jones, E. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612183152503 · Cited by 972
Soloway, R. D., Summerskill, W. H. J., Baggenstoss, A. H., Geall, M. G., Gitnick, G. L., Elveback, L. R., & Schoenfield, L. J. (1972) · Gastroenterology · doi:10.1016/s0016-5085(19)33223-8 · Cited by 779
Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features
Dienstag, J. L. (1983) · Gastroenterology · doi:10.1016/0016-5085(83)90336-0 · Cited by 500
Self-citationSporadic Non-A, Non-B Hepatitis: Frequency and Epidemiology in an Urban U.S. Population
Alter, M. J., Gerety, R. J., Smallwood, L. A., Sampliner, R. E., Tabor, E., Deinhardt, F., Frosner, G., & Matanoski, G. M. (1982) · Journal of Infectious Diseases · doi:10.1093/infdis/145.6.886 · Cited by 222
Non-A, Non-B Posttransfusion Hepatitis—A Decade Later
Koretz, R. L., Stone, O., Mousa, M., & Gitnick, G. (1985) · Gastroenterology · doi:10.1016/s0016-5085(85)80087-1 · Cited by 128
The interferon system in acute and chronic viral hepatitis.
Peters, M. J., Gl, D., Dooley, J. S., & Hoofnagle, J. H. (1986) · PubMed · Cited by 87
Cited by
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Self-citationYoshioka, K., Kakumu, S., Wakita, T., Ishikawa, T., Itoh, Y., Takayanagi, M., Higashi, Y., Shibata, M., & Morishima, T. (1992) · Hepatology · doi:10.1002/hep.1840160203 · Cited by 668
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Bonkovsky, H. L., & Woolley, M. J. (1999) · Hepatology · doi:10.1002/hep.510290124 · Cited by 398
Metadata
- Authors
- Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., VanThiel, D. H., Tamburro, C., Lefkowitch, J., Albrecht, J., Meschievitz, C., Ortego, T. J., Gibas, A., & The Hepatitis Interventional Therapy Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1989-11-30
- Volume
- 321
- Issue
- 22
- Pages
- 1501-1506
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336799715
- Cited by
- 1,633
- References
- 9
- FWCI
- 52.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa. https://app.cochat.ai/papers/10.1056/nejm198911303212203
- The paper
- Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., VanThiel, D. H., Tamburro, C., Lefkowitch, J., Albrecht, J., Meschievitz, C., Ortego, T. J., Gibas, A., & The Hepatitis Interventional Therapy Group. (1989). Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa. New England Journal of Medicine. https://doi.org/10.1056/nejm198911303212203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.